Ensayo clínico

Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

NCT: NCT07285668 · RECRUITING

ID NCTNCT07285668

EstadoRECRUITING

Fecha de inicio2026-02-26

SponsorUniversity of Wisconsin, Madison (OTHER)

First posted2025-12-16

Last updated2026-09-14

Resumen breve

This study is being done to assess the safety and determine the maximum tolerable dose (MTD) of TCRαβ+/CD19+-depleted Donor Lymphocyte Infusion (αβT/B dep-DLI) after allogeneic stem cell transplant (allo-SCT) in highrisk patients with hematologic malignancies.

Fuente oficial

Ver en ClinicalTrials.gov →

Datos obtenidos de la API de ClinicalTrials.gov. Para conocer el estado más reciente, consulte el registro oficial.